In addition, lenalidomide enhances the in vivo antitumor activity of siremadlin in Merkel cell carcinoma–derived cell lines (47); hence, FPFT-2216 may prove effective against various cancers by targeting the CK1α/p53 signaling pathway. This evidence concerns the gene TP53 and cancer.